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1. INTRODUCTION
The HER2 gene (formerly called c-erbB-2) encodes
a 185-kDa transmembrane glycoprotein with intra-
cellular tyrosine kinase activity. In breast cancer,
overexpression of HER2 is seen in 20%–30% of
breast cancer cases 1. Initially, the goal of HER2 sta-
tus assessment for breast cancer was to determine
which patients with metastatic disease might benefit
from treatment with trastuzumab (Herceptin:
Genentech, San Francisco, CA, U.S.A.), the mono-
clonal antibody to HER2, either alone or in combi-
nation with chemotherapy. Subsequently, the HER2
status of breast tumours was shown to have a poten-
tial role in the selection of adjuvant systemic therapy
because of prognostic relevance and a putative role
in predicting resistance to specific chemotherapies
and hormonal therapies. Accordingly, some centres
routinely tested for tumour HER2 status at the time
of diagnosis.
At the 2005 meeting of the American Society of
Clinical Oncology, early reports from three random-
ized studies demonstrated a 50% improvement in
disease-free survival and a 33% improvement in over-
all survival with the addition of trastuzumab to stan-
dard adjuvant chemotherapy. Thus, it is now essential
that HER2 status be available at the time of breast
cancer diagnosis. Although medical oncologists will
use this information to determine the need for adju-
vant trastuzumab, the extent to which HER2 status
might affect their adjuvant chemotherapy and hor-
monal therapy recommendations is not known.
Amplification of HER2 has been found to corre-
late with a worse prognosis in both node-negative
and node-positive disease 2–4. However, whether pa-
tients with such amplification would benefit from
receiving more aggressive systemic therapy than they
might otherwise receive is still unknown. Reports
about the ability of HER2 overexpression to predict
response to systemic chemotherapy and hormonal
therapy are conflicting. Studies have suggested that,
as compared with patients without HER2 over-
expression, patients with such overexpression ben-
efit less from chemotherapy regimens that lack an
anthracycline 5–7. It has also been suggested that pa-
tients with HER2 overexpression are resistant to
tamoxifen 8 and that alternative strategies such as
aromatase inhibition or ovarian oblation or both may
be superior in these patients 9. However, other stud-
ies have not found HER2 overexpression to adversely
influence response to tamoxifen 10. Interpretation of
the data is further complicated by the fact that large
discrepancies exist between centres worldwide with
respect to the method of detecting HER2 gene over-
expression 11,12.
Despite the uncertainties, some authors advo-
cated—long before the release of the promising ad-
juvant trastuzumab data—that, because of its
prognostic usefulness, HER2 testing be routinely
performed for all new breast cancer cases 13. In On-
tario, the most populous province in Canada, such
routine testing was adopted at some centres, but not
at others. Accordingly, to better understand whether
and how HER2 status affects systemic chemotherapy
and hormonal therapy recommendations by medical
oncologists, we conducted a survey of those practi-
tioners across Ontario.
2. MATERIALS AND METHODS
An introductory letter, consent form, and question-
naire were mailed to all medical oncologists practic-
ing at cancer centres and teaching hospitals in Ontario,
and to all community oncologists across Ontario who
were members of the Canadian Association of Medi-
cal Oncologists at the time of mailing. Medical
oncologists who did not regularly treat breast cancer
were excluded. A total of 99 packages were mailed
in September 2002.
The questionnaire was divided into two sections:
• Section 1 gathered demographic data, including
the physician’s age, years in practice, type of prac-
tice, and percentage of time devoted to treating
oncology patients in general and breast cancer
patients in particular. The questionnaire also
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asked about the availability to the physician of
common prognostic and predictive factors in
breast cancer, including tumour size, tumour
grade, oestrogen receptor (ER) and progesterone
receptor (PR) expression, lymphovascular inva-
sion, perineural invasion, lymph node involve-
ment, and HER2 overexpression.
• Section 2 of the questionnaire was designed in
two separate versions (version A and version B).
Both versions contained five hypothetical sce-
narios of newly diagnosed breast cancer cases for
which an adjuvant treatment decision was re-
quested. Cases with a risk of recurrence ranging
from low to high were included. Each scenario
supplied patient demographic data as well as in-
formation on the primary tumour, including size,
grade, lymphovascular invasion, ER/PR status, and
lymph node involvement. In each case scenario,
HER2/neu overexpression was also included and
listed as positive (HER2+) or negative (HER2–).
Questionnaire versions A and B differed only
with respect to the HER2 status of each case.
Version A scenarios 1, 3, and 5 were marked as
HER2+, and scenarios 2 and 4 as HER2–;
version B scenarios reversed the HER2 status of
each case. The medical oncologists were random-
ized to receive either questionnaire version A or
version B, with stratification by cancer centre.
The oncologists were blinded to the specific study
hypothesis and were told in the letter that the project
was evaluating the availability and utility of prog-
nostic and predictive markers for decision-making
in the adjuvant treatment of breast cancer. Written
informed consent was obtained from all participants.
For each case scenario, physicians were instructed
to choose from a list of systemic treatment options
one or more regimens that they would recommend.
The chemotherapy regimens included were CMF, CEF,
AC, AC plus Taxol, CAF, and MF (see Table I for a de-
scription of these regimens—information that was
included with the questionnaire). The options of
choosing no chemotherapy or an alternative regimen
not listed were also provided.
In addition to the systemic chemotherapy options,
systemic hormonal therapy options were added for
the two hormone receptor–positive cases. The op-
tions included were tamoxifen, aromatase inhibitor,
ovarian ablation (surgical or medical)—either alone
or in combination—and “other therapy.” The ques-
tionnaire assumed that some form of hormonal
therapy would be offered. Table II shows one sample
case scenario from the questionnaire.
For the purpose of analysis, each case scenario
was classified as showing a low, intermediate, or high
risk of recurrence, based on projected 10-year dis-
ease-free survival according to Mayo Clinic criteria 14.
Each physician’s systemic chemotherapy recom-
mendation for a given scenario was grouped into one
of three categories: “no chemotherapy,” “less aggres-
sive” (CMF, AC, or MF), and “more aggressive” (AC plus
Taxol, CEF, FAC, or CAF). If regimens from more than
one category were chosen, the selection was recorded
as “less aggressive” because, presumably, the physi-
cian would opt to treat the patient with the least toxic
of the regimens selected. If no chemotherapy was
selected as one of the choices, then regardless of other
selections, “no chemotherapy” was recorded. The
number of physicians specifically recommending ei-
ther or both of AC and CMF was noted. For the two
case scenarios with hormone-receptor-positive dis-
ease, endocrine therapy was coded as either “tamoxi-
fen” or “other.”
All results with ordered categories (that is, “no
chemotherapy,” “less aggressive,” and “more aggres-
sive” chemotherapy) were analyzed using chi-square
for trend. Variables with two categories were ana-
lyzed using the Fisher exact test.
3. RESULTS
Of the 99 medical oncologists to whom questionnaires
were mailed, 50 received version A (group A) and
49 received version B (group B). The group A phy-
sicians returned 30 questionnaires. One questionnaire
was incompletely answered; the remaining 29 were
included in the final analysis. The group B physicians
returned 29 completed questionnaires. Both groups
had similar male:female ratios, mean years in prac-
tice, and type of practice (Table III). At the time of
consultation, HER2 status was routinely available in
53% and 55% of cases in groups A and B respec-
tively. The other prognostic and predictive factors
included in the questionnaire were almost universally
routinely available to both groups.
3.1 Scenario 1
Scenario 1 presented a 47-year-old woman with a
0.6-cm, grade 3, ER/PR-negative, node-negative infil-
trating ductal carcinoma (low risk, 90% disease-free
survival at 10 years 14). We observed no significant
difference in treatment recommendations between the
group A and B physicians [Figure 1(a)]. Also, among
physicians recommending less aggressive chemo-
therapy, the proportion of those choosing AC as com-
pared with CMF did not differ by HER2 status (4/13
vs. 6/17).
3.2 Scenario 2
Scenario 2 presented a 59-year-old woman with a
1.5-cm, grade 2, ER/PR-positive, node-negative infil-
trating ductal carcinoma (intermediate risk, 81% dis-
ease-free survival at 10 years). Physicians who
received the HER2+ version of the scenario were
more likely to select some form of adjuvant chemo-
therapy [21/29 vs. 10/29, p = 0.008, Figure 1(b)].SURVEY: HER2 AND ADJUVANT BREAST CANCER TREATMENT
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Among the physicians who selected less aggressive
chemotherapy, a higher proportion of those receiv-
ing the HER2+ version recommended AC over CMF
(3/9 vs. 3/18), but the difference was not statistically
significant (p = 0.37).
For adjuvant endocrine treatment [Figure 2(a)],
a tendency to favour aromatase inhibitors over tamox-
ifen was seen among the oncologists who received
the HER2+ version (5/29 vs. 1/29, p = 0.19).
3.3 Scenario 3
Scenario 3 presented a 65-year-old woman with a
2.2-cm, grade 2, ER/PR-positive infiltrating ductal car-
cinoma metastatic to 2 of 11 axillary nodes (high risk,
50% disease-free survival at 10 years). Of the
oncologists who received the HER2+ version, only 1
of 29 selected “no chemotherapy” as compared with
5 of the 29 who received the HER2– version (p = 0.13).
TABLE II Sample case scenario
In the following case scenarios, while more than one treatment option might be appropriate for patient discussion, please assume the patient
has informed you that she does not want to be part of any clinical trial and wishes you to make the decision about her treatment. Please tick
off the best treatment option. Please circle more than one answer if you believe 2 or more of the options given are entirely equivalent in terms
of efficacy in that particular case. (See [Table I] for definitions of treatment regimens described)
An otherwise healthy 59 y.o. woman presents post-mastectomy with ER +ve, PR +ve, grade II, 1.5 cm infiltrating duct carcinoma with
focal tumour necrosis but no LVI or perineural involvement. HER2/neu overexpression is “positive.” Twelve lymph nodes are negative for
malignancy.
What systemic treatment would you recommend?
a) Hormonal therapy only
b) AC × 4, then hormonal therapy
c) CMF × 6, then hormonal therapy
d) AC × 4, then Taxol × 4, then hormonal therapy
e) CAF or FAC × 6 months, then hormonal therapy
f) MF × 6 months, then hormonal therapy
g) CEF × 6 months, then hormonal therapy
h) Other chemotherapy  (please specify regimen and duration: _______________________________), then hormonal therapy
What hormonal therapy would you recommend?
Tamoxifen
An aromatase inhibitor
Other (please specify: __________________________________)
TABLE I Chemotherapy regimens
Regimen Agent and dose Cycle
AC Doxorubicin 60 mg/m2 IV, day 1 Every 21 days
Cyclophosphamide 600 mg/m2 IV, day 1
AC + Taxol Doxorubicin 60 mg/m2 IV, day 1 Every 21 days × 4
Cyclophosphamide 600 mg/m2 IV, day 1
then
Paclitaxel 125 mg/m2, day 1 Every 21 days × 4
CMF Cyclophosphamide 100 mg/m2 PO, days 1–14 Every 28 days
Methotrexate 40 mg/m2 IV, days 1 and 8
5-Fluorouracil 600 mg/m2 IV, days 1 and 8
MF Methotrexate 100 mg/m2 IV, days 1 and 8 Every 28 days
5-Fluorouracil 600 mg/m2 IV, days 1 and 8 1 Hour after methotrexate
Leucovorin 10 mg/m2 PO Starting 24 hours after methotrexate, every 6 h × 6 doses
CAF Cyclophosphamide 100 mg/m2 PO, days 1–14 Every 28 days
Doxorubicin 30 mg/m2 IV, days 1 and 8
5-Fluorouracil 500 mg/m2 IV, days 1 and 8
CEF 5-Fluorouracil 500 mg/m2 IV, days 1 and 8 Every 28 days
Epirubicin 60 mg/m2 IV, days 1 and 8
Cyclophosphamide 75 mg/m2 PO, days 1–14
FAC 5-Fluorouracil 500 mg/m2 IV, day 1 Every 21 days
Doxorubicin 50 mg/m2 IV, day 1
Cyclophosphamide 500 mg/m2 IV, day 1
IV = intravenous; PO = orally.MYERS et al.
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No statistically significant difference was seen in the
aggressiveness of the chemotherapy recommended
[Figure 1(c)], nor in the choice of AC over CMF.
3.4 Scenario 4
Scenario 4 presented a 43-year-old woman with a
1.7-cm, grade 3, ER/PR-negative, node-negative infil-
trating ductal carcinoma (intermediate risk, 81% dis-
ease-free survival at 10-years). All respondents
TABLE III Physician characteristics by questionnaire version
Version A Version B
Responded [n/N (%)] 30/50 (60) 29/49 (59)
Male:female (n) 21:9 20:9
Mean training time (years) 14.2 15.1
Area of practice
Cancer centre 11 11
Academic 7 5
Community 12 13
Mean new patients per month (n) 8.7 10.5
Breast-cancer practice (%) 38% 40%
HER2 routinely available [n/N (%)] 16/30 (53) 16/29 (55)
FIGURE 1 Chemotherapy choices by the surveyed physicians for the case scenarios presented. All tumours were infiltrating ductal carcinoma:
a) Age 47, 0.6 cm, grade 3, estrogen receptor negative (ER–), node-negative; b) age 59, 1.5 cm, grade 2, ER+, node-negative; c) age 65,
2.2 cm, grade 2, ER+, node-positive; d) age 43, 1.7 cm, grade 3, ER–, node-negative; e) age 37, grade 2, 1.1 cm, ER+, node-positive.SURVEY: HER2 AND ADJUVANT BREAST CANCER TREATMENT
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selected adjuvant chemotherapy regardless of HER2
status. Of the physicians who received the HER2+
version of the scenario, 20 of 29 recommended ag-
gressive chemotherapy as compared with 14 of 29 who
received the HER2– version [p = 0.18, Figure 1(d)].
Among the physicians who selected less aggres-
sive chemotherapy, the proportion of those choosing
AC over CMF did not differ by HER2 status.
3.5 Scenario 5
Scenario 5 presented a 37-year-old woman with a
1.1-cm,  ER/PR-positive, grade 2 infiltrating ductal car-
cinoma with 2 of 16 nodes positive for cancer (high
risk, 56% disease-free survival at 10-years). All re-
spondents selected some form of adjuvant chemo-
therapy. No difference was seen between group A and
B physicians in the recommendation of less aggres-
sive (5/29 with HER2+, 4/29 with HER2–) versus
aggressive chemotherapy [Figure 1(e)], and no sig-
nificant difference was seen between the two groups
in the selection of AC over CMF.
In the group that received the HER2+ version of
the questionnaire, hormonal treatments other than
tamoxifen were more frequently recommended, with
8 of 29 physicians choosing ovarian ablation with or
without an aromatase inhibitor in the HER2+ group
and only 2 of 29 choosing non–tamoxifen based treat-
ment in the HER2– group [p = 0.08, Figure 2(b)].
3.6 Additional Analyses
The data were also analyzed looking exclusively at
respondents who indicated that HER2 testing was rou-
tinely performed at diagnosis in their place of prac-
tice (32 total, 16 from group A and 16 from group B).
We noted statistically significant differences in the
chemotherapy recommendations for scenarios 2 and
4, both of which were intermediate-risk cases. In sce-
nario 2, 14 of 16 physicians who received the HER2+
version of the question recommended chemotherapy
as compared with only 4 of 16 who received the
HER2– version (p = 0.004). In scenario 4, for which
all oncologists recommended chemotherapy, 12 of 14
who received the HER2+ version of the question se-
lected aggressive chemotherapy as compared with just
6 of 16 who received the HER2– version (p = 0.009).
4. DISCUSSION AND CONCLUSION
The results of our survey suggest that medical
oncologists in Ontario use HER2 status to guide their
adjuvant chemotherapy and hormonal therapy treat-
ment recommendations for breast cancer cases with
an intermediate risk of recurrence.
For the low-risk case, HER2 status did not influ-
ence chemotherapy selection; however, given that
more than 60% of the oncologists recommended che-
motherapy in the low-risk scenario, it is conceivable
that HER2 status might have a greater impact even
on a lower-risk case (that is, similar to the first sce-
nario, but ER-positive). Recommendations for the two
high-risk cases were not affected by HER2 status.
That finding makes intuitive clinical sense because,
for cases already considered high risk based on more
traditional prognostic factors, additional information
would not be needed to persuade the oncologist to
recommend aggressive treatment.
We also saw a trend toward the increased use of
hormonal treatments other than tamoxifen for HER2+
cases. It is difficult to discern from the survey whether
the lack of statistical significance of that trend is an
artefact of the modest sample size or a true reflection
of varying interpretations of the literature.
The effect of HER2 status was more pronounced
among oncologists for whom HER2 was routinely
available at diagnosis. Presumably, these physicians
already routinely incorporated HER2 status into their
decision-making, and those who lacked routine HER2
information did not. However, it is also conceivable
that only the oncologists who felt strongly about the
importance of HER2 status for determining adjuvant
treatment would have pushed to have the test rou-
FIGURE 2 Hormonal therapy choices by the surveyed physicians
for estrogen receptor positive (ER+) scenarios. All tumours were
infiltrating ductal carcinoma: a) age 59; b) age 37.MYERS et al.
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tinely performed for all newly diagnosed breast can-
cer cases at their centre.
One limitation of this study is that our hypotheti-
cal cases may or may not accurately reflect the “real
world.” However, 170 consecutive charts of newly
diagnosed early-stage breast cancer patients at our
centre were systematically reviewed by one of the
authors (JAM). For cases with a profile resembling
any of the study scenarios, the range and frequency
of the actual treatment recommendations were simi-
lar to those among the survey responses for the cor-
responding hypothetical scenario.
Although our 60% response rate is above aver-
age for most mailed physician surveys 15, it is con-
ceivable that our results may not be easily generalized
to the non-responders. However, systematic differ-
ences between participants and non-participants with
respect to HER2 status utilization would be unlikely
because all potential participants were blinded to the
study hypothesis.
More important than the question of whether
HER2 status in breast cancer influences adjuvant
chemotherapy and hormonal therapy treatment deci-
sion-making is whether HER2 should influence treat-
ment decision-making at all. The most recent version
of Adjuvant! (version 7.0), the popular computer
software aid to adjuvant breast cancer therapy deci-
sion-making, allows users to insert additional prog-
nostic markers of their own choosing but it does not
specifically include HER2 in the initial profile 16.
Sufficiently powered prospective clinical trials in
which HER2 testing methodology is standardized are
clearly necessary to clarify whether modifying adju-
vant chemotherapy and hormonal therapy according
to HER2 status can favourably alter the natural his-
tory of breast cancer. In the meantime, a formal state-
of-the-art practice guideline on the use of breast
cancer HER2 status for adjuvant chemotherapy and
hormonal therapy decision-making would be ex-
tremely helpful to medical oncologists.
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